Mining for Potent Inhibitors through Artificial Intelligence and Physics: A Unified Methodology for Ligand Based and Structure Based Drug Design.
暂无分享,去创建一个
Rommie E. Amaro | Mojtaba Haghighatlari | Conor Parks | Jie Li | Oufan Zhang | Kunyang Sun | Xingyi Guan | T. Head‐Gordon | Fiona L. Kearns | Dorian Bagni | Yingze Wang
[1] Chang-Yu Hsieh,et al. ResGen is a pocket-aware 3D molecular generation model based on parallel multiscale modelling , 2023, Nature Machine Intelligence.
[2] S. Murmu,et al. Insilico generation of novel ligands for the inhibition of SARS-CoV-2 main protease (3CLpro) using deep learning , 2023, Frontiers in Microbiology.
[3] H. Liu,et al. LS-MolGen: Ligand-and-Structure Dual-Driven Deep Reinforcement Learning for Target-Specific Molecular Generation Improves Binding Affinity and Novelty , 2023, J. Chem. Inf. Model..
[4] Shikui Tu,et al. AlphaDrug: protein target specific de novo molecular generation , 2022, PNAS nexus.
[5] Rommie E. Amaro,et al. Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors , 2022, bioRxiv.
[6] Hongming Chen,et al. De Novo Molecule Design Using Molecular Generative Models Constrained by Ligand-Protein Interactions , 2022, J. Chem. Inf. Model..
[7] Y. Orba,et al. Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19 , 2022, Journal of medicinal chemistry.
[8] Jike Wang,et al. InteractionGraphNet: A Novel and Efficient Deep Graph Representation Learning Framework for Accurate Protein-Ligand Interaction Predictions. , 2021, Journal of medicinal chemistry.
[9] Hu Haifeng,et al. Accelerating AutoDock Vina with GPUs , 2021, Molecules.
[10] Farren J. Isaacs,et al. Potent Noncovalent Inhibitors of the Main Protease of SARS-CoV-2 from Molecular Sculpting of the Drug Perampanel Guided by Free Energy Perturbation Calculations , 2021, ACS central science.
[11] T. Laino,et al. Data-driven molecular design for discovery and synthesis of novel ligands: a case study on SARS-CoV-2 , 2021, Mach. Learn. Sci. Technol..
[12] V. Dubey,et al. Microsecond MD Simulation and Multiple-Conformation Virtual Screening to Identify Potential Anti-COVID-19 Inhibitors Against SARS-CoV-2 Main Protease , 2021, Frontiers in Chemistry.
[13] Sowmya Ramaswamy Krishnan,et al. De novo design of new chemical entities for SARS-CoV-2 using artificial intelligence , 2021, Future medicinal chemistry.
[14] Haitao Yang,et al. Recent Progress in the Drug Development Targeting SARS-CoV-2 Main Protease as Treatment for COVID-19 , 2020, Frontiers in Molecular Biosciences.
[15] Yurii S. Moroz,et al. Generating Multibillion Chemical Space of Readily Accessible Screening Compounds , 2020, iScience.
[16] Dongsup Kim,et al. Autonomous molecule generation using reinforcement learning and docking to develop potential novel inhibitors , 2020, Scientific Reports.
[17] Benjamin A. Shoemaker,et al. PubChem in 2021: new data content and improved web interfaces , 2020, Nucleic Acids Res..
[18] Hualiang Jiang,et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors , 2020, Nature.
[19] Reaz Uddin,et al. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach , 2020, Journal of biomolecular structure & dynamics.
[20] Wonpil Im,et al. Improving Protein-Ligand Docking Results with High-Throughput Molecular Dynamics Simulations , 2020, J. Chem. Inf. Model..
[21] Jeremy Howard,et al. fastai: A Layered API for Deep Learning , 2020, Inf..
[22] Alán Aspuru-Guzik,et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors , 2019, Nature Biotechnology.
[23] Sangdun Choi,et al. A Structure-Based Drug Discovery Paradigm , 2019, International journal of molecular sciences.
[24] Alán Aspuru-Guzik,et al. Self-referencing embedded strings (SELFIES): A 100% robust molecular string representation , 2019, Mach. Learn. Sci. Technol..
[25] Marwin H. S. Segler,et al. GuacaMol: Benchmarking Models for De Novo Molecular Design , 2018, J. Chem. Inf. Model..
[26] Eugene N. Muratov,et al. QSAR-Based Virtual Screening: Advances and Applications in Drug Discovery , 2018, Front. Pharmacol..
[27] Alán Aspuru-Guzik,et al. Inverse molecular design using machine learning: Generative models for matter engineering , 2018, Science.
[28] Adrian J Mulholland,et al. Multiscale Methods in Drug Design Bridge Chemical and Biological Complexity in the Search for Cures. , 2018, Nature reviews. Chemistry.
[29] Sepp Hochreiter,et al. Fréchet ChemNet Distance: A Metric for Generative Models for Molecules in Drug Discovery , 2018, J. Chem. Inf. Model..
[30] Nicholay Topin,et al. Super-convergence: very fast training of neural networks using large learning rates , 2018, Defense + Commercial Sensing.
[31] Olexandr Isayev,et al. Deep reinforcement learning for de novo drug design , 2017, Science Advances.
[32] Thomas Blaschke,et al. Molecular de-novo design through deep reinforcement learning , 2017, Journal of Cheminformatics.
[33] Olivier Michielin,et al. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules , 2017, Scientific Reports.
[34] John J. Irwin,et al. ZINC 15 – Ligand Discovery for Everyone , 2015, J. Chem. Inf. Model..
[35] Michael Schroeder,et al. PLIP: fully automated protein–ligand interaction profiler , 2015, Nucleic Acids Res..
[36] Jayme L. Dahlin,et al. PAINS in the Assay: Chemical Mechanisms of Assay Interference and Promiscuous Enzymatic Inhibition Observed during a Sulfhydryl-Scavenging HTS , 2015, Journal of medicinal chemistry.
[37] Alexandre Varnek,et al. Estimation of the size of drug-like chemical space based on GDB-17 data , 2013, Journal of Computer-Aided Molecular Design.
[38] Douglas R. Houston,et al. Consensus Docking: Improving the Reliability of Docking in a Virtual Screening Context , 2013, J. Chem. Inf. Model..
[39] Hélène Decornez,et al. Early phase drug discovery: cheminformatics and computational techniques in identifying lead series. , 2012, Bioorganic & medicinal chemistry.
[40] G. V. Paolini,et al. Quantifying the chemical beauty of drugs. , 2012, Nature chemistry.
[41] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[42] M. Mezei,et al. Molecular docking: a powerful approach for structure-based drug discovery. , 2011, Current computer-aided drug design.
[43] A. Olson,et al. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..
[44] Matthias Rarey,et al. On the Art of Compiling and Using 'Drug‐Like' Chemical Fragment Spaces , 2008, ChemMedChem.
[45] Matthias Rarey,et al. Towards an Integrated Description of Hydrogen Bonding and Dehydration: Decreasing False Positives in Virtual Screening with the HYDE Scoring Function , 2008, ChemMedChem.
[46] Daniel James,et al. Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases , 2007, ChemMedChem.
[47] T. O'Brien,et al. Fragment-based drug discovery. , 2004, Journal of medicinal chemistry.
[48] J. Ziebuhr,et al. Conservation of substrate specificities among coronavirus main proteases. , 2002, The Journal of general virology.
[49] Gordon M. Crippen,et al. Prediction of Physicochemical Parameters by Atomic Contributions , 1999, J. Chem. Inf. Comput. Sci..
[50] Boris Polyak,et al. Acceleration of stochastic approximation by averaging , 1992 .